Showing results (1901-1910 of 3,016) with videos related to
Sort By:
Pageof 302
European Journal of Obstetrics, Gynecology, and Reproductive Biology|March 13, 2024
Chemotherapy response score as a predictor of survival in ovarian cancer patientsIoannis Rodolakis, Michalis Liontos, Vasilios Pergialiotis, et al.Journal of Personalized Medicine|June 25, 2026
Precision Medicine in Inherited Retinal Disease: Advances, Challenges, and Future DirectionsThanansayan Dhivagaran, Fahad R Butt, Krystal Grover, et al.Current Oncology (Toronto, Ont.)|December 13, 2021
What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of ExperienceMichalis Liontos, Anna Svarna, Charalampos Theofanakis, et al.Oncology|August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experienceGeorge Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.Intensive Care Medicine|April 27, 2017
Diagnostic work-up and specific causes of acute kidney injuryMichael Darmon, Marlies Ostermann, Jorge Cerda, et al.European Journal of Haematology|March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairmentMeletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.Circulation|September 16, 2015
Survival Prospects and Circumstances of Death in Contemporary Adult Congenital Heart Disease Patients Under Follow-Up at a Large Tertiary CentreGerhard-Paul Diller, Aleksander Kempny, Rafael Alonso-Gonzalez, et al.Haematologica|March 3, 2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administrationEvangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, et al.Anticancer Research|January 4, 2012
Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2Paris A Kosmidis, Konstantinos Syrigos, Haralampos P Kalofonos, et al.Anticancer Research|March 6, 2014
Low protein expression of MET in ER-positive and HER2-positive breast cancerFlora Zagouri, Anita Brandstetter, Dimitrios Moussiolis, et al.Pageof 302